Elda Righi - Infectious Diseases

Author Information

Elda Righi is an esteemed researcher affiliated with The University of Queensland Centre for Clinical Research (UQCCR) at the Royal Brisbane and Women's Hospital in Herston, Queensland, Australia. Additionally, she is associated with the Infectious Diseases department of the Department of Diagnostics and Public Health at the University of Verona, Italy. Her expertise lies in the field of Infectious Diseases, where she contributes significantly to clinical research and public health.

Research Contributions

Elda Righi has made substantial contributions to the field of Infectious Diseases, with a particular focus on the efficacy and safety of treatments for complicated infections, the management of long COVID symptoms, and the clinical management of infections caused by resistant bacteria. Notable studies include systematic reviews and meta-analyses on carbapenem-resistant Gram-negative bacteria and the impact of COVID-19. Her research is pivotal in advancing the understanding and treatment of severe infections, especially in the context of antibiotic resistance.

Aliases

Throughout her career, Elda Righi has been referenced under various aliases, including E Righi, E. Righi, and Elda Righi.

Publication and Citation Metrics

Metric	Value
Citation Count	7692
h-index	45
Paper Count	196

Publications:

Efficacy and Safety of Carbapenems vs New Antibiotics for Treatment of Adult Patients With Complicated Urinary Tract Infections: A Systematic Review and Meta-analysis

DOI: 10.1093/ofid/ofaa480

Year: 2022

Determinants of persistence of symptoms and impact on physical and mental wellbeing in Long COVID: A prospective cohort study

DOI: 10.1016/j.jinf.2022.02.003

Year: 2022

The ESCMID ethics advisory committee (EEAC): purpose and challenges

DOI: 10.1016/j.cmi.2022.01.002

Year: 2022

A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency

DOI: 10.1007/s40121-021-00404-y

Year: 2021

Carbapenemase-producing Enterobacteriaceae in transplant patients.

DOI: 10.1093/jac/dkaa495

Year: 2021

Assessment of COVID-19 progression on day 5 from symptoms onset

DOI: 10.1186/s12879-021-06596-5

Year: 2021

Identifying COVID-19 Progression by Day Five From Symptoms Onset

DOI: 10.21203/RS.3.RS-470829/V1

Year: 2021

Clinical Efficacy of Combination Therapy for the Treatment of Severe Infections Caused by Carbapenem Resistant Gram-Negatives. A Systematic Review of Clinical Studies

DOI: 10.21203/RS.3.RS-366344/V1

Year: 2021

Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.

DOI: 10.1016/j.ijantimicag.2021.106344

Year: 2021

Clinical management of severe infections caused by carbapenem-resistant Gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations.

DOI: 10.1016/j.cmi.2021.05.002

Year: 2021

Why is Awareness Important?

What is a Urinary Tract Infection (UTI)?

When to Use Decongestants?

How is Hepatitis B Diagnosed?

What are Common Adverse Effects of Antimicrobial Drugs?

What is Fatty Acid Biosynthesis?

How is Malaria Diagnosed?

What Could Be Causing Weight Loss?

What Role Does the Immune System Play?

What Causes Damage to the Host?

Partnered Content Networks

Relevant Topics